Products being developed are therapeutic agents to be used in the treatment of cognitive impairment with neurodegenerative disorders
Suven Life Sciences received the grant of one product patent from India (274974) and another from Japan (5981654). Corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases, these patents are valid through 2026 and 2032 respectively.
The granted claims of the patents include the class of selective 5-HT6 compounds and H3 inverse agonist compounds. They are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder, Huntington’s disease, Major Depressive Disorder, Parkinson and Schizophrenia.
EP News Bureau